1. Home
  2. Exits
  3. Optinose, Inc.

Optinose commercialized XHANCE, an innovative drug delivery system that delivers steroids high and deep into the nasal cavity for the treatment of chronic sinusitis. Paratek Pharmaceuticals acquired Optinose in 2025.

Latest news

Paratek Pharmaceuticals agrees to acquire Optinose
March 19, 2025
Zimmer Biomet agrees to acquire Paragon 28
January 28, 2025
GT Medical Technologies Raises $37 Million in Series D to Advance the Expansion of GammaTile® in the U.S. for Patients with Operable Brain Tumors
January 16, 2025
icotec Receives FDA Clearance for Spinal Infection Indication with BlackArmor® implants
January 14, 2025
OSSIO Raises $27.6 Million to Accelerate Its Commercial Engine as High Demand for Bio-Integrative Fixation Technology Continues
December 2, 2024
Hologic agrees to acquire Gynesonics
October 14, 2024
eXmoor Pharma Partners with Quell Therapeutics to Develop CAR-Treg Cell Therapies
September 24, 2024
Stryker agrees to acquire Vertos Medical
August 22, 2024
eXmoor Pharma’s GMP cell and gene therapy manufacturing facility receives license from MHRA
August 20, 2024
Providence Medical Technology, Inc. Announces FDA Clearance of CORUS™ Navigation Access System for Use with Medtronic’s StealthStation™ Surgical Navigation in Posterior Spinal Fusion
June 13, 2024
View all